Advertisement
Screener

BIO-TECHNE Corp (TECH) Goodwill, Acquired During Period

2.8 / 5 stars · 68/120 Roast Me

BIO-TECHNE Corp Goodwill, Acquired During Period

BIO-TECHNE Corp (TECH) reported Goodwill, Acquired During Period of $104.65 million for the 12-month period ending 2024-06-30, per its 10-K filed 2025-08-22.

Financial Statements › Notes › Goodwill and Other

us-gaap:GoodwillAcquiredDuringPeriod · last filed 2025-08-22

  • BIO-TECHNE Corp goodwill, acquired during period for the quarter ending 2024-06-30 was $2.10M, a 921.36% increase year-over-year.
  • BIO-TECHNE Corp goodwill, acquired during period for the quarter ending 2024-03-31 was $0.00.
  • BIO-TECHNE Corp goodwill, acquired during period for the quarter ending 2023-12-31 was -$14.00K.
  • BIO-TECHNE Corp goodwill, acquired during period for the quarter ending 2023-09-30 was $102.56M, a 100.90% increase year-over-year.
  • BIO-TECHNE Corp goodwill, acquired during period for fiscal 2024 was $104.65M, a 104.17% increase from fiscal 2023.
  • BIO-TECHNE Corp goodwill, acquired during period for fiscal 2023 was $51.26M.
  • BIO-TECHNE Corp goodwill, acquired during period for fiscal 2021 was $102.82M.
  • BIO-TECHNE Corp goodwill, acquired during period for fiscal 2019 was $136.30M, a 613.77% increase from fiscal 2018.
Period endGoodwill, Acquired During Period 3 monthGoodwill, Acquired During Period 6 monthGoodwill, Acquired During Period 9 monthGoodwill, Acquired During Period 12 monthGoodwill, Acquired During Period 12 month as first filed
2024-06-30$2.10M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-08-22
$2.10M
derived: sum of 2 quarters · filed 2025-08-22
$2.09M
derived: sum of 3 quarters · filed 2025-08-22
$104.65M
10-K · filed 2025-08-22
2024-03-31$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-06
-$14.00K
derived: sum of 2 quarters · filed 2024-05-06
$102.55M
10-Q · filed 2024-05-06
$102.75M
derived: sum of 4 quarters · filed 2024-05-06
2023-12-31-$14.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-07
$102.55M
10-Q · filed 2024-02-07
$102.75M
derived: sum of 3 quarters · filed 2024-02-07
$102.75M
derived: sum of 4 quarters · filed 2024-02-07
2023-09-30$102.56M
10-Q · filed 2023-11-07
$102.77M
derived: sum of 2 quarters · filed 2023-11-07
$102.77M
derived: sum of 3 quarters · filed 2023-11-07
$102.77M
derived: sum of 4 quarters · filed 2023-11-07
2023-06-30$206.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-08-23
$206.00K
derived: sum of 2 quarters · filed 2023-08-23
$206.00K
derived: sum of 3 quarters · filed 2023-08-23
$51.26M
10-K · filed 2023-08-23
2023-03-31$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-08
$0.00
derived: sum of 2 quarters · filed 2023-05-08
$51.05M
10-Q · filed 2023-05-08
2022-12-31$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-02-07
$51.05M
10-Q · filed 2023-02-07
2022-09-30$51.05M
10-Q · filed 2022-11-07
2022-03-31$4.41M
10-Q · filed 2022-05-09
2021-06-30$102.82M
10-K · filed 2022-08-24
2021-03-31$7.85M
10-Q · filed 2021-05-07
2020-12-31$8.81M
10-Q · filed 2021-02-08
2020-03-31$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-05-11
$0.00
derived: sum of 2 quarters · filed 2020-05-11
$0.00
10-Q · filed 2020-05-11
$12.65M
derived: sum of 4 quarters · filed 2020-08-26
2019-12-31$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-02-06
$0.00
10-Q · filed 2020-02-06
$12.65M
derived: sum of 3 quarters · filed 2020-08-26
$23.72M
derived: sum of 4 quarters · filed 2020-08-26
2019-09-30$0.00
10-Q · filed 2019-11-06
$12.65M
derived: sum of 2 quarters · filed 2020-08-26
$23.72M
derived: sum of 3 quarters · filed 2020-08-26
$29.92M
derived: sum of 4 quarters · filed 2020-08-26
2019-06-30$12.65M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-08-26
$23.72M
derived: sum of 2 quarters · filed 2020-08-26
$29.92M
derived: sum of 3 quarters · filed 2020-08-26
$136.30M
10-K · filed 2020-08-26
2019-03-31$11.07M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-05-07
$17.27M
derived: sum of 2 quarters · filed 2019-05-07
$123.65M
10-Q · filed 2019-05-07
$114.94M
derived: sum of 4 quarters · filed 2019-11-06
2018-12-31$6.20M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-02-07
$112.58M
10-Q · filed 2019-02-07
$103.88M
derived: sum of 3 quarters · filed 2019-11-06
$125.69M
derived: sum of 4 quarters · filed 2019-11-06
2018-09-30$106.38M
10-Q · filed 2018-11-07
$97.68M
derived: sum of 2 quarters · filed 2019-11-06
$119.49M
derived: sum of 3 quarters · filed 2019-11-06
$120.88M
derived: sum of 4 quarters · filed 2019-11-06
2018-06-30-$8.70M
derived: 10-K/A 12 month − 10-Q 9 month · filed 2019-11-06
$13.11M
derived: sum of 2 quarters · filed 2019-11-06
$14.50M
derived: sum of 3 quarters · filed 2019-11-06
$19.10M
10-K/A · filed 2019-11-06
2018-03-31$21.81M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-05-09
$23.20M
derived: sum of 2 quarters · filed 2018-05-09
$27.80M
10-Q · filed 2018-05-09
$33.73M
derived: sum of 4 quarters · filed 2018-08-27
2017-12-31$1.40M
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-02-08
$5.99M
10-Q · filed 2018-02-08
$11.92M
derived: sum of 3 quarters · filed 2018-08-27
$22.89M
derived: sum of 4 quarters · filed 2018-08-27
2017-09-30$4.59M
10-Q · filed 2017-11-09
$10.52M
derived: sum of 2 quarters · filed 2018-08-27
$21.49M
derived: sum of 3 quarters · filed 2018-08-27
$11.38M
derived: sum of 4 quarters · filed 2018-08-27
2017-06-30$5.93M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-08-27
$16.90M
derived: sum of 2 quarters · filed 2018-08-27
$6.79M
derived: sum of 3 quarters · filed 2018-08-27
$147.48M
10-K · filed 2018-08-27
2017-03-31$10.97M
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-05-10
$863.00K
derived: sum of 2 quarters · filed 2017-05-10
$141.56M
10-Q · filed 2017-05-10
$139.47M
derived: sum of 4 quarters · filed 2017-09-07
2016-12-31-$10.11M
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-02-09
$130.59M
10-Q · filed 2017-02-09
$128.50M
derived: sum of 3 quarters · filed 2017-09-07
$137.22M
derived: sum of 4 quarters · filed 2017-09-07
2016-09-30$140.69M
10-Q · filed 2016-11-09
$138.61M
derived: sum of 2 quarters · filed 2017-09-07
$147.32M
derived: sum of 3 quarters · filed 2017-09-07
$147.24M
derived: sum of 4 quarters · filed 2017-09-07
2016-06-30-$2.09M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-07
$6.63M
derived: sum of 2 quarters · filed 2017-09-07
$6.55M
derived: sum of 3 quarters · filed 2017-09-07
$49.55M
10-K · filed 2017-09-07
$49.65M
10-K · filed 2016-08-29
2016-03-31$8.72M
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-05-10
$8.63M
derived: sum of 2 quarters · filed 2016-05-10
$51.63M
10-Q · filed 2016-05-10
$53.23M
derived: sum of 4 quarters · filed 2016-08-29
2015-12-31-$81.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-02-09
$42.92M
10-Q · filed 2016-02-09
$44.52M
derived: sum of 3 quarters · filed 2016-08-29
$37.48M
derived: sum of 4 quarters · filed 2016-08-29
2015-09-30$43.00M
10-Q · filed 2015-11-09
$44.60M
derived: sum of 2 quarters · filed 2016-08-29
$37.56M
derived: sum of 3 quarters · filed 2016-08-29
$140.94M
derived: sum of 4 quarters · filed 2016-08-29
2015-06-30$1.60M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-08-29
-$5.44M
derived: sum of 2 quarters · filed 2016-08-29
$97.94M
derived: sum of 3 quarters · filed 2016-08-29
$254.14M
10-K · filed 2016-08-29
2015-03-31-$7.04M
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-05-11
$96.34M
derived: sum of 2 quarters · filed 2015-05-11
$252.54M
10-Q · filed 2015-05-11
2014-12-31$103.38M
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-02-09
$259.58M
10-Q · filed 2015-02-09
2014-09-30$156.20M
10-Q · filed 2014-11-10
2014-06-30$61.87M
10-K · filed 2015-08-31
2012-06-30$0.00
10-K · filed 2012-08-29
2011-06-30$62.87M
10-K · filed 2012-08-29
2010-06-30$0.00
10-K · filed 2011-08-29

Similar stocks

Stock NameCountryMarket CapPE Ratio
Twist Bioscience Corp (TWST)United States$11.540B-47.21
REPLIGEN CORP (RGEN)United States$10.755B185.31
Krystal Biotech, Inc. (KRYS)United States$10.210B45.56
HALOZYME THERAPEUTICS, INC. (HALO)United States$13.083B21.59
Kymera Therapeutics, Inc. (KYMR)United States$9.631B-31.69
ImmunityBio, Inc. (IBRX)United States$9.157B-9.29
NEUROCRINE BIOSCIENCES INC (NBIX)United States$14.131B24.25
Vaxcyte, Inc. (PCVX)United States$8.466B-7.91
EXELIXIS, INC. (EXEL)United States$14.358B16.15
Immunovant, Inc. (IMVT)United States$7.028B-14.78